UPDATE 1-Labopharm posts wider Q3 loss as revenue falls 30 pct

* Q3 loss C$0.12/shr vs loss C$0.11/shr year-ago

* Revenue falls 30 pct to C$6.6 mln

* Says to cut 35 jobs

Nov 6 (Reuters) - Labopharm Inc (DDS.TO) (DDSS.O) posted a wider quarterly loss, as the Canadian drugmaker earned lower licensing revenue from its once-daily tramadol pain treatment and said it would cut about 35 jobs under plan to streamline operations.

For the third quarter, the company reported loss of C$6.9 million, or 12 Canadian cents a share, compared with loss of C$6 million, or 11 Canadian cents a share, a year ago.

Total revenue fell 30 percent to C$6.6 million. The company had reported total revenue of C$9.4 million a year ago, which included non-recurring licensing revenue of C$4.4 million.

Labopharm's licensing revenue, which includes payments received from licensing and distribution partners for its once-daily tramadol pain treatment fell 78 percent to C$1.2 million.

Shares of the company were down 2 Canadian cents at C$1.79 Friday morning on the Toronto Stock Exchange. (Reporting by Ashutosh Joshi in Bangalore; Editing by Jarshad Kakkrakandy)